AUTHORS
Laura Rolke, PhD, MPH, Danielle Boselli, MS2, Jing Ai, MD, PhD3, Brittany Knick Ragon, MD4, Aleksander Chojecki, MD5, Nilay Shah, MD6, Srinivasa Reddy Sanikommu, MD7, Kelly Brook Weaver, DNP, APRN, ACNS-BC, NP-C, OCN, AOCNP8, Lawrence J Druhan, PhD9, Michael R. Grunwald, MD10, Thomas G Knight, MD11
AFFILIATIONS
1 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
2 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
3 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
4 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
5 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
6 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
7 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
8 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
9 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
10 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
11 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
ABSTRACT
Introduction: Survival for adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) has improved with therapy advances, but outcomes remain heterogeneous and may be shaped by financial factors outside the healthcare system. Most population-based disparities studies rely on broad composite socioeconomic indices rather than specific measures of financial distress. Debt in collections is a concrete community-level measure of financial burden that may serve as a marker of local economic vulnerability and the financial context in which cancer care is delivered. The purpose of this study is to assess if county-level share of debt in collections is associated with inferior 5-year survival outcomes in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients.
Methods: We conducted a retrospective cohort study using the National Cancer Institute’s specialized SEER 17 Research Plus Incidence Database (covering 26.5% of the U.S. population) with county-level identifiers. AYAs (15 to 39 years old) were included in this study if they had a diagnosis of ALL (AYA ICD-O-3 definition) and were diagnosed between 2003 and 2017. Patients were excluded if they were diagnosed at death or autopsy, had no survival time, or had incomplete survival data. The Urban Institute’s Debt in America county-level debt dataset (2025) was matched by FIPS codes to SEER patients. Counties across the United States were placed into quintiles based on the proportion of county residents with any debt in collections (ranging from 5.9% to 48.3%). Descriptive statistics, Kaplan Meier methods, and Cox proportional hazards models were analyzed in R Studio; 5-year overall survival (OS) and cancer-specific survival (CSS) models were constructed (covariates include sex, age group, race/ethnicity, and diagnosis time period).
Results: The study cohort included 4,279 AYAs. Most patients were male (n=2,752, 64.3%); Hispanic (n= 1,976, 46.2%), and non-Hispanic White (n=1,610, 37.6%) patients represented the largest racial and ethnic groups. Age distribution was relatively even across groups, with 36.0% of patients aged 15-19 years (n=1,542), 35.0% aged 20-29 years (n=1,520), and 28.4% aged 30-39 years (n=1,217). Patients were unequally distributed across county-level debt quintiles as follows: Q1 (32.7%, n=1,401), Q2 (29.4%, n=1,260), Q3 (21.8%, n=933), Q4 (8.3%, n=356), and Q5 (7.7%, n=329).
Five-year OS was lowest among patients living in counties with the greatest debt burden, though survival did not decline uniformly across each quintile: Q1: 63.2%, Q2: 57.6%, Q3: 56.2%, Q4: 58.6%, and Q5: 54.9%. A similar pattern was observed for 5-year CSS: Q1: 67.0%, Q2: 60.6%, Q3: 61.1%, Q4: 62.0%, and Q5: 59.6%.
In a continuous multivariable Cox regression model, higher county-level debt burden was independently associated with an increased risk of death, corresponding to a 13.7% higher hazard of death for every 10-percentage-point increase in the proportion of residents with debt in collections (HR=3.61 per 100-percentage-point increase in the proportion of residents with debt in collections; p<0.001). Compared with patients in the lowest-debt counties, higher mortality was observed in Q3 (HR=1.18, 95% CI: 1.03-1.35, p<0.05) and Q5 (HR=1.34, 95% CI: 1.10-1.61, p<0.01). Covariates behaved as expected, with older age and Hispanic ethnicity are significantly associated with increased mortality risk, whereas more recent year of diagnosis was associated with lower mortality risk.
Conclusions: Among AYAs with ALL, residence in counties with a greater proportion of debt in collections was associated with inferior 5-year survival outcomes after adjustment for demographic and diagnosis-period factors. These findings identify debt in collections as a measurable marker of community financial distress associated with leukemia outcomes. Incorporating county-level debt metrics into routine screening may offer a scalable approach to identify AYA patients with acute leukemia who are at risk for inferior survival and could benefit from proactive financial intervention at diagnosis.
DISCLOSURES
Thomas G Knight, MD: No relevant conflicts of interest to declare.